By Vijay Kumar MalesuMay 28 2024Reviewed by Lily Ramsey, LLM In a recent study published in the Journal of Clinical Medicine , a group of researchers described the clinical characteristics of patients with type 2 diabetes initiating oral semaglutide and assessed its effects on glycemic control, body weight , and tolerability in routine clinical practice.
Its efficacy in glycemic control, BW reduction, and safety have been consistently demonstrated in the Peptide Innovation for Early Diabetes Treatment trials program, which includes ten randomized controlled trials involving 9,543 subjects with T2D. About the study The present study was conducted in two Italian university-based diabetes centers using data from the Metaclinic/Medical Technology and Diagnostic Applications electronic chart system.
Oral semaglutide was initiated with a 4-week dose-escalation regimen, starting at 3 mg, followed by 7 mg, and increasing to 14 mg if tolerated.
Semaglutide Type 2 Diabetes Agonist Blood Blood Pressure Cholesterol Chronic Efficacy Food Glucagon Glucagon-Like Peptide-1 Glucose Hba1c Medicine Receptor Research Weight Loss
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide shows significant weight loss and health benefits in four-year obesity studyA study in Nature Medicine evaluated the effects of semaglutide on weight and anthropometric outcomes in adults with obesity but without diabetes, finding significant weight loss and improved health metrics over four years. The study also highlighted the safety and tolerability of semaglutide across different BMI categories.
Source: NewsMedical - 🏆 19. / 71 Read more »
‘If NHS can afford it, people with obesity should have Semaglutide,’ says weight loss expertWe were joined by Professor Frank Joseph, a weight loss expert who was one of the investigators in the study.
Source: Channel4News - 🏆 27. / 68 Read more »
Sustainable weight loss with personalized semaglutide dosingNew research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has explored the benefits of giving personalised doses of semaglutide to patients taking part in a weight loss programme and tapering them off the medication when they reach their target weight.
Source: NewsMedical - 🏆 19. / 71 Read more »
Semaglutide improves heart failure symptoms and reduces loop diuretic doseSemaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction (HFpEF) regardless of diuretic use, according to late breaking research presented today at Heart Failure 2024, a scientific congress of the European...
Source: NewsMedical - 🏆 19. / 71 Read more »
Semaglutide significantly reduces risk of complications in patients with type 2 diabetes, study revealsA pioneering study has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease.
Source: medical_xpress - 🏆 101. / 51 Read more »
Semaglutide may protect kidney function in individuals with overweight or obesity and cardiovascular diseaseThe SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.
Source: medical_xpress - 🏆 101. / 51 Read more »